| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6149940 | CONCORDIA | Tablet with controlled release of alfuzosine chlorhydrate |
Aug, 2017
(6 years ago) | |
|
US6149940 (Pediatric) | CONCORDIA | Tablet with controlled release of alfuzosine chlorhydrate |
Feb, 2018
(6 years ago) | |
Uroxatral is owned by Concordia.
Uroxatral contains Alfuzosin Hydrochloride.
Uroxatral has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Uroxatral are:
- US6149940
- US6149940*PED
Uroxatral was authorised for market use on 12 June, 2003.
Uroxatral is available in tablet, extended release;oral dosage forms.
The generics of Uroxatral are possible to be released after 22 February, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-97) | Dec 15, 2013 |
| Pediatric Exclusivity(PED) | Jun 15, 2014 |
Drugs and Companies using ALFUZOSIN HYDROCHLORIDE ingredient
Market Authorisation Date: 12 June, 2003
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of UROXATRAL before it's drug patent expiration?
More Information on Dosage
UROXATRAL family patents
